Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s R&D marches on

Executive Summary

"I'm pleased to say, R&D marches on," Bristol-Myers Squibb Chief Scientific Officer Elliott Sigal says at a recent strategic alliances conference in New York. "I am glad to be here, actually I'm pleased to get out period," he adds. Bristol's robust pipeline is one reason the firm has been rumored to be an acquisition candidate following the termination of CEO Peter Dolan Sept. 12 on the heels of a failed settlement with Apotex over Plavix generics (1"The Pink Sheet" Sept. 18, 2006, p. 3)...

You may also be interested in...



Bristol Interim CEO Pick Fuels Acquisition Rumors, Complicating Search

Bristol-Myers Squibb's search for a new CEO may be complicated by the widespread belief that the company is an acquisition target

QUOTED. 29 September 2020. Phil Brown.

ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.

COVID-19 Vaccines: HHS Advisory Committee Urges ‘Great Caution’ On Use Of EUA

Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel